| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner | Director
4 companies
Woiwode Thomas is a Director, 10% Owner at Passage BIO, Inc. with holdings across 4 companies. Recent SEC Form 4 filings include 3 buys and 32 sells.
Estimated insider holdings value: $56.3M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2022 | TPST Tempest Therapeutics, Inc. | Director, 10% Owner | Buy | 2,118,644 | $2.36 | $4,999,999.84 | New | -41.3% | -41.3% | |
| Oct 20, 2020 | ALGS Aligos Therapeutics, Inc. | Director | Buy | 200,000 | $15.00 | $3,000,000.00 | +30.2% | - | - | |
| Mar 3, 2020 | PASG Passage Bio, Inc. | Director, 10% Owner | Buy | 225,000 | $18.00 | $4,050,000.00 | +31.8% | - | - | |
| May 15, 2018 | CRSP Crispr Therapeutics AG | Director | Sell | 44,000 | $57.99 | $2,551,440.00 | -3.3% | - | - | |
| May 8, 2018 | CRSP Crispr Therapeutics AG | Director | Sell | 121,362 | $50.39 | $6,115,872.59 | -4.3% | - | - | |
| Apr 30, 2018 | CRSP Crispr Therapeutics AG | Director | Sell | 30,566 | $50.29 | $1,537,137.92 | -2.0% | - | - | |
| Apr 27, 2018 | CRSP Crispr Therapeutics AG | Director | Sell | 222,258 | $50.11 | $11,136,437.01 | -6.8% | - | - | |
| Apr 24, 2018 | CRSP Crispr Therapeutics AG | Director | Sell | 22,841 | $50.99 | $1,164,655.40 | -1.3% | - | - | |
| Apr 23, 2018 | CRSP Crispr Therapeutics AG | Director | Sell | 101,994 | $50.68 | $5,168,901.34 | -5.5% | - | - | |
| Dec 22, 2017 | CRSP Crispr Therapeutics AG | Director | Sell | 3,059 | $20.29 | $62,070.47 | -38.2% | - | - |